Experience

Davis Polk advised the placement agent in connection with a private placement pursuant to Rule 4(a)(2) by Humanigen Inc. of $72 million of common stock. Humanigen Inc. is a clinical…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a $175 million SEC-registered common stock and pre-funded warrants…

Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by NuVasive, Inc. of $400 million aggregate principal amount of its 1.000%…

Davis Polk advised Penumbra, Inc. on its SEC-registered follow-on public offering of 865,963 shares of common stock for an aggregate price to the public of approximately $143.75 million,…

Davis Polk advised the joint book-running managers and representatives of the initial purchasers in connection with a Rule 144A offering by 1Life Healthcare, Inc. of $275 million…

Davis Polk advised the representatives of the underwriters in connection with the $70 million follow-on public offering of 5,000,000 shares of common stock of TransMedics Group, Inc…

Davis Polk advised the representatives of the several underwriters in connection with an SEC-registered offering by DENTSPLY SIRONA Inc. of $750 million aggregate principal amount of…

Davis Polk advised the representatives of the underwriters in connection with the $60 million SEC-registered follow-on offering of ordinary shares of Gamida Cell Ltd. The ordinary…

Davis Polk advised the joint book-running managers in connection with a $325 million SEC-registered common stock offering by Turning Point Therapeutics, Inc. The common stock is listed…

Davis Polk advised ADC Therapeutics SA on its SEC-registered initial public offering of 14,082,475 common shares, which included the exercise in full by the underwriters of their option to…